依达拉奉注射液治疗急性脑梗塞的疗效与不良反应的Meta分析

Meta-analysis of Efficacy and Adverse Reaction of Edaravone Injection in the Treatment of Acute Cerebral Infarction

目的初步评价依达拉奉注射液临床应用的疗效及不良反应。方法应用Meta分析对20篇文献中研究依达拉奉注射液与其他对照组药物治疗急性脑梗塞的疗效及不良反应进行同质性检验及合并效应量的估计。结果(1)同质性检验:疗效,χ2=9.52;不良反应,χ2=3.10,P值均大于0.05,均具有同质性,可以分别合并结果。(2)合并效应量的估计:疗效,OR合并=3.89,OR合并95%CI[3.02,5.02],OR合并的检验:χ2=10.47,P<0.05;安全性,OR合并=2.08,OR合并95%CI[1.19,3.64],OR合并的检验:x2=2.57,P<0.05。结论依达拉奉注射液治疗急性脑梗塞的疗效总体上优于对照组,治疗组的不良反应明显高于对照组。

Objective To evaluate the clinical efficacy and adverse reaction of Edaravone injection in the treatment of acute cerebral infarction. Methods The efficacy and adverse reaction of Edaravone injection versus other drugs of control group in the treatment of acute cerebral infarction reported in 20 research papers were subjected to homogeneity test and combined test using meta-analysis. Results Homogeneity test showed that the cited studies of efficacy and adverse reaction were homogeneous with X2=9.52, X2=3.10（P〉0.05）.In combined test, the combined ORe=3.89 （95% confidence interval ranged from 3.02 to 5.02, x2=-10.47, P 〈0.05） and combined ORs=2.08（95% confidence interval 1.19-3.64, X2=2.57, P〈0.05）. Conclusion Clinical efficacy of Edaravone injection is significantly better than that of other drugs in treatment of acute cerebral infarction. But the incidence of ADK induced by Edaravone injection is higher than other drugs-induced ADR.